Dates: April 18-22, 2026
Location: McCormick Place, Chicago, Illinois, USA
Organizer: American Academy of Neurology
Website: aanannualmeeting.com
The clinical trials track at AAN 2026 presents results from major ongoing and completed clinical studies in neurological disorders. This page covers key presentations across neurodegenerative diseases, stroke, epilepsy, multiple sclerosis, and neuromuscular conditions.
- TRAILBLAZER-ALZ 2: Longer-term follow-up data
- Real-world effectiveness: Clinical practice outcomes
- ARIA management: Updated protocols and guidelines[@cummings2024]
- TRAILBLAZER-ALZ 2: Full results and subgroup analyses
- Clinical implementation: Practical considerations
- Patient selection: Biomarker-guided approaches
- Next-generation antibodies: Phase 2/3 results
- Small molecules: Oral tau aggregation inhibitors
- Combination approaches: Multi-target strategies
- Immunotherapies: Longevity, JNJ-63733657
- Small molecules: Tau aggregation inhibitors
- Novel mechanisms: Phase 1/2 results
- A4 Study: Anti-amyloid in preclinical AD
- DIAN-TU: Dominantly inherited AD prevention
- API: Alzheimer's Prevention Initiative
- Prasinezumab: Phase 2b results and future plans
- PD01A/PD03A: Active immunotherapy programs
- Aggregation inhibitors: Preclinical and early clinical
- LRRK2 inhibitors: Clinical development status
- GBA-targeted approaches: For GBA mutation carriers
- AAV-based delivery: Early-phase results
- RNAi approaches: Gene silencing strategies
- Thrombolysis: Extended time window studies
- Thrombectomy: Patient selection criteria
- Combination approaches: Bridging therapies
- Anticoagulation: Direct oral anticoagulants
- Antiplatelet strategies: Dual vs. single therapy
- Closure devices: PFO closure outcomes
- Prevention strategies: Blood pressure, lifestyle
- Trial design: Cognitive endpoints
- B-cell therapies: Ofatumumab, ocrelizumab
- S1P modulators: Fingolimod, siponimod
- Cladribine: Long-term safety and efficacy
- Ocrelizumab: Primary progressive MS results
- Bruton's tyrosine kinase inhibitors
- Remyelination strategies
- Treatment response: Predictors of efficacy
- Safety monitoring: Biomarker-driven approaches
- New agents: Cannabidiol, fenfluramine
- Generic equivalents: Bioequivalence studies
- Special populations: Pediatric, elderly
- Responsive neurostimulation (RNS)
- Vagus nerve stimulation (VNS)
- Deep brain stimulation
- Laser ablation: MR-guided stereotactic
- Responsive devices: Closed-loop systems
- Riluzole: Real-world effectiveness
- Edaravone: Clinical trial extensions
- Gene therapies: SOD1, C9orf72
- Onasemnogene abeparvovec: Long-term outcomes
- Spinraza: Repeated dosing
- Evrysdi: Real-world data
- Eculizumab: Generalized MG results
- Rozanolixizumab: FcRn antagonists
- Efgartigimod: Novel mechanisms
- Blood-based biomarkers: Screening and enrichment
- Imaging biomarkers: Patient selection
- Digital biomarkers: Remote monitoring
- Platform trials: Master protocols
- Adaptive designs: Sample size re-estimation
- Hybrid designs: Traditional and real-world evidence
- FDA guidance: Alzheimer's disease endpoints
- EMA perspectives: European regulatory views
- Patient-reported outcomes: Novel endpoints
- AAN 2026 Annual Meeting
- ClinicalTrials.gov
- Cummings et al., Anti-amyloid therapy outcomes (2024)
- AAIC 2026 Clinical Trials